Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
Gossamer Bio和其他2支股票在$2以下，內部人士正在購買。
The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道瓊斯指數週一收盤上漲超過250點。當內部人員購買或出售股票時，表明他們對公司前景的信心或擔憂。有興趣投資或交易便士股票的投資者和交易者可以考慮這一因素對其整體投資或交易決策的影響。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是幾個近期關於低價股的值得關注的內部交易。了解更多，請查看Benzinga內幕交易平台。
Pacific Health Care Organization
太平洋保健組織
- The Trade: Pacific Health Care Organization, Inc. (NASDAQ:PFHO) CEO and President Tom Kubota bought a total of 6,270 shares at an average price of $0.88. To acquire these shares, it cost around $5,543.
- What's Happening: The company reported net income of $176,427 or $0.01 per share for the three months ended June 30, 2023.
- What Pacific Health Care Organization Does: Pacific Health Care Organization Inc is a specialty workers' compensation managed care company.
- 交易：太平洋保健組織股票（NASDAQ:PFHO）的首席執行官兼總裁Tom Kubota以平均價格0.88美元購買了共6270股。購買這些股票需要花費約5543美元。
- 現狀：公司報告了2023年6月30日結束的三個月的淨利潤爲176,427美元或每股0.01美元。
- 太平洋保健組織是一家專業的工人賠償管理保健公司。
System1
System1
- The Trade: System1, Inc. (NYSE:SST) 10% owner Cee Holdings Trust acquired a total of 8,013 shares at an average price of $1.44. To acquire these shares, it cost around $11,575.
- What's Happening: On May 9, System1 posted upbeat first-quarter results.
- What System1 Does: System1 Inc develops technology and data science to operate a responsive acquisition marketing platform.
- 交易：System1, Inc.（NYSE:SST）的10％股東Cee Holdings Trust以平均價格1.44美元收購了共8013股。購買這些股票需要花費約11,575美元。
- 現狀：5月9日，System1發佈了樂觀的第一季度業績報告。
- System1 Inc開發技術和數據科學，以運營響應式收購營銷平台。
Gossamer Bio
Gossamer Bio
- The Trade: Gossamer Bio, Inc. (NASDAQ:GOSS) President and CEO Faheem Hasnain acquired a total of 372,000 shares at an average price of $0.67. The insider spent around $250,282 to buy those shares.
- What's Happening: On June 25, Oppenheimer analyst Andreas Argyrides initiated coverage on Gossamer Bio with an Outperform rating and announced a price target of $9.
- What Gossamer Bio Does: Gossamer Bio Inc is a clinical-stage biopharmaceutical company.
- 交易：Gossamer Bio, Inc.（NASDAQ:GOSS）的總裁兼首席執行官Faheem Hasnain以平均價格0.67美元購買了共372,000股。這位內部人士花費約250,282美元購買這些股票。
- 現狀：6月25日，Oppenheimer分析師Andreas Argyrides對Gossamer Bio進行了覆蓋，評級爲Outperform，並宣佈了9美元的目標價。
- Gossamer Bio Inc是一家處於臨床階段的生物製藥公司。
Read More: Stocks To Watch On Tuesday: Boeing, FedEx And More
更多閱讀：星期二要關注的股票：波音、聯邦快遞等
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間